His acolytes are discovering that it’s not so much about any particular policy as having blind faith in the man himself ...

As part of Xenon's ongoing collaboration with Neurocrine Biosciences, a Phase 1 study is underway of NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and ...

First Quarter 2025 Earnings Conference Call and Webcast: ...

Your guide to what Trump’s second term means for Washington, business and the world Donald ... from energy to auto manufacturing. The Financial Times reported this week that the White House ...

For full-year 2025, the Company expects to generate approximately $265 million of Adjusted Free Cash Flow at current oil prices of ~$59 per barrel WTI, inclusive of hedging proceeds, and to reduce Net ...

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa”), a clinical-stage specialty biopharmaceutical company developing ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company”) today announced financial results for the first quarter ended March 31, 2025.

At March 31, 2025, the Company's cash and cash equivalents grew to $938.5 million, compared to $912.8 million at December 31, 2024, after prepaying a $50.0 million deposit related to our Evergreen ...

Initiates Full Year 2025 Revenue Guidance of approximately $38 million ...

Revenue for the second fiscal quarter ended March 31, 2025, was $2.2 million as compared to $2.5 million for the same period in the prior year, a decrease of 14.2%. Cost of goods sold was $1.6 million ...

CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialysis customers. The Company's first quarter of 2025 was ...